July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Very early effects of intravitreal aflibercept and bevacizumab injections for retinal vein occlusion: comparison of 2 drugs
Author Affiliations & Notes
  • Masaki Shibata
    Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasakishi, Japan
  • Yutaka Imamura
    Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasakishi, Japan
  • Asuka Takeyama
    Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasakishi, Japan
  • Rieko Kato
    Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasakishi, Japan
  • Masahiro Ishida
    Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasakishi, Japan
  • Footnotes
    Commercial Relationships   Masaki Shibata, None; Yutaka Imamura, None; Asuka Takeyama, None; Rieko Kato, None; Masahiro Ishida, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4273. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masaki Shibata, Yutaka Imamura, Asuka Takeyama, Rieko Kato, Masahiro Ishida; Very early effects of intravitreal aflibercept and bevacizumab injections for retinal vein occlusion: comparison of 2 drugs. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4273.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate functional and anatomical effects of intravitreal aflibercept (IVA) and bevacizumab (IVB) injections for retinal vein occlusion, and possible differences between 2 drugs very shortly after treatment.

Methods : LogMAR visual acuity, central macular thickness and subfoveal choroidal thickness in patients with retinal vein occlusion undergoing either alibercept or bevacizumab injection were retrospectively analysed. Changes of the parameters at 1 day and 1 week after injection were compared between IVA and IVB groups.

Results : There were 42 eyes of 42 patients (22 females, mean age: 68.7 years) including 42 eyes with retinal vein occlusions, which had not been treated previously. The change rates of central retinal thickness of IVA group (N=18) and IVB group (N=24) were 55.17±15.01% and 75.85±15.78% at 1day after injection (unpaired t test, P<0.001) and 40.52±15.46% and 46.58±23.96% at 1 week (P=0.451) respectively. The change rates of subfoveal choroidal thicknesses of IVA and IVB were 91.18±15.74% and 101.20±9.67% (P=0.022) at 1day and 84.07±14.13% and 96.11±6.39% (P=0.016) at 1 week, respectively. Changes of LogMAR visual acuity were not different between the 2 groups (P=0.715 at 1day and P=0.095 at 1 week).

Conclusions : Aflibercept appears to make retina and choroid thinner than bevacizumab shortly after injection, whose long-term significance for functional outcomes remains to be elucidated.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×